179 related articles for article (PubMed ID: 34791304)
21. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
22. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
[TBL] [Abstract][Full Text] [Related]
23. Endocrine toxicity in cancer patients treated with nivolumab or pembrolizumab: results of a large multicentre study.
Presotto EM; Rastrelli G; Desideri I; Scotti V; Gunnella S; Pimpinelli N; Vaccher E; Bearz A; Di Costanzo F; Bruggia M; Mini E; Maggi M; Peri A
J Endocrinol Invest; 2020 Mar; 43(3):337-345. PubMed ID: 31542865
[TBL] [Abstract][Full Text] [Related]
24. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
[TBL] [Abstract][Full Text] [Related]
25. The glucocorticoids prednisone and dexamethasone differentially modulate T cell function in response to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade.
Okoye IS; Xu L; Walker J; Elahi S
Cancer Immunol Immunother; 2020 Aug; 69(8):1423-1436. PubMed ID: 32246174
[TBL] [Abstract][Full Text] [Related]
26. Predicting response and toxicity to PD-1 inhibition using serum autoantibodies identified from immuno-mass spectrometry.
Music M; Iafolla M; Soosaipillai A; Batruch I; Prassas I; Pintilie M; Hansen AR; Bedard PL; Lheureux S; Spreafico A; Razak AA; Siu LL; Diamandis EP
F1000Res; 2020; 9():337. PubMed ID: 33299547
[No Abstract] [Full Text] [Related]
27. Targeting CTLA-4 in cancer: Is it the ideal companion for PD-1 blockade immunotherapy combinations?
De Silva P; Aiello M; Gu-Trantien C; Migliori E; Willard-Gallo K; Solinas C
Int J Cancer; 2021 Jul; 149(1):31-41. PubMed ID: 33252786
[TBL] [Abstract][Full Text] [Related]
28. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Delanoy N; Michot JM; Comont T; Kramkimel N; Lazarovici J; Dupont R; Champiat S; Chahine C; Robert C; Herbaux C; Besse B; Guillemin A; Mateus C; Pautier P; Saïag P; Madonna E; Maerevoet M; Bout JC; Leduc C; Biscay P; Quere G; Nardin C; Ebbo M; Albigès L; Marret G; Levrat V; Dujon C; Vargaftig J; Laghouati S; Croisille L; Voisin AL; Godeau B; Massard C; Ribrag V; Marabelle A; Michel M; Lambotte O
Lancet Haematol; 2019 Jan; 6(1):e48-e57. PubMed ID: 30528137
[TBL] [Abstract][Full Text] [Related]
29. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
[TBL] [Abstract][Full Text] [Related]
30. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis.
Bertrand A; Kostine M; Barnetche T; Truchetet ME; Schaeverbeke T
BMC Med; 2015 Sep; 13():211. PubMed ID: 26337719
[TBL] [Abstract][Full Text] [Related]
31. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
32. Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer.
Muir CA; Menzies AM; Clifton-Bligh R; Tsang VHM
Thyroid; 2020 Oct; 30(10):1458-1469. PubMed ID: 32264785
[No Abstract] [Full Text] [Related]
33. Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms.
Delivanis DA; Gustafson MP; Bornschlegl S; Merten MM; Kottschade L; Withers S; Dietz AB; Ryder M
J Clin Endocrinol Metab; 2017 Aug; 102(8):2770-2780. PubMed ID: 28609832
[TBL] [Abstract][Full Text] [Related]
34. Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer.
Osorio JC; Ni A; Chaft JE; Pollina R; Kasler MK; Stephens D; Rodriguez C; Cambridge L; Rizvi H; Wolchok JD; Merghoub T; Rudin CM; Fish S; Hellmann MD
Ann Oncol; 2017 Mar; 28(3):583-589. PubMed ID: 27998967
[TBL] [Abstract][Full Text] [Related]
35. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.
Kobayashi T; Iwama S; Yasuda Y; Okada N; Tsunekawa T; Onoue T; Takagi H; Hagiwara D; Ito Y; Morishita Y; Goto M; Suga H; Banno R; Yokota K; Hase T; Morise M; Hashimoto N; Ando M; Kiyoi H; Gotoh M; Ando Y; Akiyama M; Hasegawa Y; Arima H
J Endocr Soc; 2018 Mar; 2(3):241-251. PubMed ID: 29600292
[TBL] [Abstract][Full Text] [Related]
36. Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy.
Brilli L; Danielli R; Campanile M; Secchi C; Ciuoli C; Calabrò L; Pilli T; Cartocci A; Pacini F; Di Giacomo AM; Castagna MG
J Endocrinol Invest; 2021 Aug; 44(8):1719-1726. PubMed ID: 33367977
[TBL] [Abstract][Full Text] [Related]
37. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
38. Immune-related adverse events following administration of anti-cytotoxic T-lymphocyte-associated protein-4 drugs: a comprehensive systematic review and meta-analysis.
Xu H; Tan P; Zheng X; Huang Y; Lin T; Wei Q; Ai J; Yang L
Drug Des Devel Ther; 2019; 13():2215-2234. PubMed ID: 31308633
[No Abstract] [Full Text] [Related]
39. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
[TBL] [Abstract][Full Text] [Related]
40. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.
Boutros C; Tarhini A; Routier E; Lambotte O; Ladurie FL; Carbonnel F; Izzeddine H; Marabelle A; Champiat S; Berdelou A; Lanoy E; Texier M; Libenciuc C; Eggermont AM; Soria JC; Mateus C; Robert C
Nat Rev Clin Oncol; 2016 Aug; 13(8):473-86. PubMed ID: 27141885
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
